New WHO guidance on GLP-1 medications With GLP-1 injections becoming increasingly popular and new GLP-1 weight-loss pills on the horizon, its only fitting that the World Health Organization (WHO) has just released new guidance on the meds
It binds to glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors hormones that stimulate insulin secretion and suppress appetite
If you are taking a GLP-1 medication like semaglutide or tirzepatide, you have probably already noticed changes in your appetite, your energy levels, and your body composition
Maintenance doses vary between individuals based on response and tolerability
Are there any side effects of taking L-carnitine
This warning states that tirzepatide causes thyroid C-cell tumors at clinically relevant exposures in rodents and that it is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans